In addition to those clinical associations, in a study of 318 SSc patients with cancer, Shah et al. reported that anti-RNPC-3 antibodies were found in 3.8% of the patients and were associated with a short cancer-scleroderma interval (median 0.9 years). Here, RNPC3 is linked to systemic sclerosis.